Scientific Journal Article Demonstrates Superiority of n3D’s Bio-Assembler
NOKOMIS, Fla. -- September 26, 2013
A recent study published in the scientific journal Biochimica et Biophysica
Acta provides an illuminating demonstration of the superiority of
three-dimensional cell cultures produced by Rainbow Coral Corp. (OTCBB: RBCC)
partner Nano3D Biosciences’ technology over traditional two-dimensional
Produced by researchers from Houston’s Baylor College of Medicine and the
Methodist Hospital Research Institute, the study reports on experiments into
the transdifferentiation of vascular smooth muscle cells into calcifying
vascular cells. The group used n3D’s Bio-Assembler technology to magnetically
levitate their cell cultures in order to produce more lifelike tissues.
The study found that the cells grew more rapidly using in 3-D than 2-D, and
differentiated in days rather than weeks. The published piece is yet more
evidence to the scientific community that the Bio-Assembler is an essential
tool for all kinds of cellular research, including disease models.
“The Bio-Assembler represents a new evolution in cell culture technology,”
said RBCC CEO Patrick Brown. “Thanks to high-profile research being conducted
using this system, word is being spread very rapidly as to the unparalleled
utility and efficiency afforded by the Bio-Assembler.”
RBCC formed a joint venture with n3D to market and develop the Bio-Assembler
last year. Rainbow Biosciences is dedicated to the marketing and development
of new medical and research technology innovations designed to help capture a
growing share of a booming biotech industry alongside Bristol Myers Squibb Co.
(NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT)
and Amgen Inc. (NASDAQ: AMGN).
For more information on RBCC’s partnership with n3D and other biotech
initiatives, please visit www.rainbowbiosciences.com/investors.html.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visitwww.RainbowBioSciences.com. For investment information and
performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
Press spacebar to pause and continue. Press esc to stop.